James R ODell
Overview
Explore the profile of James R ODell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
3008
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
ODell J, Brophy M, Pillinger M, Neogi T, Palevsky P, Wu H, et al.
NEJM Evid
. 2022 Apr;
1(3).
PMID: 35434725
Background: The relative efficacy and safety of allopurinol and febuxostat when used according to current guidelines for the treatment of hyperuricemia are unknown. This double-blind noninferiority trial examined these issues....
12.
Helget L, England B, Roul P, Sayles H, Petro A, Neogi T, et al.
Arthritis Care Res (Hoboken)
. 2022 Mar;
75(4):808-816.
PMID: 35294114
Objective: To compare all-cause and cause-specific mortality risk between patients with gout and patients without gout in the Veteran's Health Administration (VHA). Methods: We performed a matched cohort study, identifying...
13.
Mikuls T, Soto Q, Petro A, Helget L, Roul P, Sayles H, et al.
JAMA Netw Open
. 2022 Jan;
5(1):e2142347.
PMID: 34989795
Importance: Cardiometabolic and other risk factors could render patients with gout more likely to undergo lower extremity amputation (LEA). Objective: To examine the rate of and factors associated with LEA...
14.
Medcalf M, Bhadbhade P, Mikuls T, ODell J, Gundry R, Funk R
Metabolites
. 2021 Dec;
11(12).
PMID: 34940582
Methotrexate (MTX) efficacy in the treatment of rheumatoid arthritis (RA) is variable and unpredictable, resulting in a need to identify biomarkers to guide drug therapy. This study evaluates changes in...
15.
Hughes-Austin J, Ix J, Ward S, Weisman M, ODell J, Mikuls T, et al.
BMJ Open
. 2021 Sep;
11(9):e050883.
PMID: 34521672
Objective: Physical activity (PA) in preclinical rheumatoid arthritis (RA) is associated with lower RA risk and disease severity. As joint signs and symptoms of inflammatory arthritis serve as a barrier...
16.
Rosenbaum J, Costenbader K, Desmarais J, Ginzler E, Fett N, Goodman S, et al.
Ophthalmology
. 2021 Mar;
128(7):1115-1116.
PMID: 33752915
No abstract available.
17.
Rosenbaum J, Costenbader K, Desmarais J, Ginzler E, Fett N, Goodman S, et al.
Arthritis Rheumatol
. 2021 Feb;
73(6):908-911.
PMID: 33559327
Four major medical societies involved with hydroxychloroquine (HCQ) therapy concur on the need for common principles and cooperation to minimize the risk of ocular toxicity. At a daily dosage of...
18.
Ptacek J, Hawtin R, Sun D, Louie B, Evensen E, Mittleman B, et al.
PLoS One
. 2021 Jan;
16(1):e0244187.
PMID: 33444321
Rheumatoid arthritis (RA) is a systemic and incurable autoimmune disease characterized by chronic inflammation in synovial lining of joints. To identify the signaling pathways involved in RA, its disease activity,...
19.
Polinski K, Bemis E, Yang F, Crume T, Demoruelle M, Feser M, et al.
Arthritis Rheumatol
. 2020 Dec;
73(6):955-962.
PMID: 33381911
Objective: To determine the association of polyunsaturated fatty acid (PUFA)-derived lipid mediators with progression from rheumatoid arthritis (RA)-related autoimmunity to inflammatory arthritis (IA). Methods: We conducted a prospective cohort study...
20.
Zhao Z, Jia Z, Foster K, Wei X, Qiao F, Jiang H, et al.
Nanomedicine
. 2020 Sep;
31:102302.
PMID: 32980548
Lupus nephritis (LN) is a major cause of morbidity and mortality among systemic lupus erythematosus patients. Glucocorticoids (GCs) are uniformly used in clinical LN management. Their notorious toxicities, however, have...